This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.

Subscribe on iTunes | Subscribe on Google Play | View in the Educational Activity

Keywords: CardiaCast, Diabetes Mellitus, Cardiotonic Agents, Sodium-Glucose Transporter 2, Metabolic Syndrome, Diabetes Mellitus, Type 2

< Back to Listings